Clinical Trial Update: Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD [Phase 2]

View source ↗

Summary

A Phase IIb clinical trial is planned to evaluate the efficacy and safety of GenSci120 Injection in adults with moderately to severely active rheumatoid arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GenSci120 Injection (GenSci120)

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: NOT_YET_RECRUITING